Jubilant Pharmova FY26 Results: Revenue Soars 14%, Dividend Proposed

Revenue ₹8,279.6 crore (FY 2026) vs ₹7,234.5 crore (FY 2025)
EBITDA ₹1,325.5 crore (FY 2026) vs ₹1,230.0 crore (FY 2025)

Reader Takeaway: Strong revenue growth but margin pressure due to operational issues needs monitoring.

What just happened

Jubilant Pharmova reported a significant 14% increase in revenue from operations for the fiscal year 2026, reaching ₹8,279.6 crore, up from ₹7,234.5 crore in the previous fiscal year. The company's Board of Directors has also recommended a final dividend of ₹5 per equity share for FY 2025-26.

Why this matters

The strong revenue growth across key segments like CDMO Sterile Injectables (+38%), Generics (+13%), and Allergy Immunotherapy (+12%) indicates healthy demand and market traction. The dividend payout signals confidence in future performance. However, a decline in EBITDA margin to 15.9% due to operational challenges at the Montreal facility and supply shortages of SPECT products presents a concern that could impact profitability.

The backstory

Jubilant Pharmova has been focusing on expanding its manufacturing capacities and product portfolio. The company's strategy includes enhancing its CDMO sterile injectables business and strengthening its generics and radiopharmaceuticals segments. The Montreal facility issues are a recent development impacting operational efficiency.

What changes now

The recommended dividend will require shareholder approval. Investors will be closely watching the company's efforts to resolve the operational issues at the Montreal facility and mitigate supply chain challenges to improve EBITDA margins in the coming quarters. The company's Vision 2030 roadmap aims for substantial revenue and margin growth.

Risks to watch

Operational headwinds at the Montreal facility, which led to temporary shutdowns and affected supply, are a key risk. Industry-wide pricing pressures in the generics segment also pose a challenge to maintaining pricing power and margins.

Peer comparison

While specific peer results are not detailed here, the pharmaceutical and contract development and manufacturing (CDMO) sectors are generally experiencing robust growth, particularly in specialized areas like sterile injectables. Competitors often face similar challenges related to facility operations, regulatory compliance, and supply chain disruptions.

Context metrics (time-bound)

For FY 2026, Jubilant Pharmova reported revenue of ₹8,279.6 crore and EBITDA of ₹1,325.5 crore. The EBITDA margin was 15.9%. The company's normalized Profit After Tax (PAT) grew 7% to ₹442.4 crore. The recommended dividend is ₹5 per equity share, with a record date of July 24, 2026.

What to track next

Investors should monitor the resolution of operational issues at the Montreal facility, the progress on capacity expansions at Spokane, and the successful execution of the Vision 2030 roadmap for revenue and margin improvement.